CGEN - Compugen Ltd. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

CGEN

COMPUGEN LTD.

NASDAQ

$2.27

▼ DOWN 1.95% (-0.04)

KEY STATISTICS

Market Cap$218.42 M

52w High$3.24

52w Low$1.43

Dividend Yield—

Frequency—

P/E5.96

Volume120.27K

Shares Out.94.55M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Eran Ophir

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 11, 2000

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$5.00

Target Low$5.00

Target Median$5.00

Target Consensus$5.00

UPCOMING EARNINGS

DateNov 9, 2026

DayMonday

Rev. Est.$1.28M

NOV

MON

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

11.63%

HOLDERS

111

TOP 8 OF 111 · RANKED BY POSITION SIZE

Silverarc Capital Management, LLC

3.5M sh

$5.32M

Renaissance Technologies LLC

Ark Investment Management LLC

1.0M sh

$2.24M

Macquarie Management Holdings, Inc.

Taylor Frigon Capital Management LLC

964.7K sh

$1.42M

Antonetti Capital Management LLC

766.5K sh

$712.87K

PRICE

$2.27 ▼ DOWN 1.95% (−$0.04)

About Compugen Ltd.

https://cgen.com ↗

Compugen Ltd. is a clinical-stage biotech in Israel, US, and Europe developing immuno-oncology therapeutics like anti-PVRIG and TIGIT antibodies, with collaborations including Bayer, Bristol-Myers Squibb, AstraZeneca, and Johns Hopkins.

INDUSTRY

Biotechnology

A PRODUCT COMPUGEN LTD. IS KNOWN FOR

Rilvegostomig

Rilvegostomig, developed by AstraZeneca, is a bispecific antibody targeting PD-1 and TIGIT (from Compugen's COM902), in Phase 3 trials for various cancers, representing a key product from Compugen's platform.

COMPETITORS

COMPETITOR

GILD COMPARE

RCUS COMPARE

Compugen in 2025

SENTIMENT: + POSITIVE

PARTNERSHIP · DECEMBER 2025

Compugen Secures Up to $90 Million by Monetizing Future Royalties from AstraZeneca Partnership

Compugen monetized a portion of its future royalties for the cancer immunotherapy drug rilvegostomig, which is in Phase 3 development by partner AstraZeneca. This agreement provides Compugen with an immediate influx of up to $90 million in non-dilutive capital, significantly strengthening its financial position and extending its operational runway into 2027.

LEADERSHIP STRATEGY · MAY 2025 · COMPLETED

Compugen Executes Strategic Leadership Transition to Steer Next Phase of Growth

Compugen enacted a significant leadership succession plan in 2025, appointing its long-serving Chief Scientific Officer, Dr. Eran Ophir, as the new President and CEO. The former President and CEO, Dr. Anat Cohen-Dayag, transitioned to the newly created, strategic role of Executive Chair of the Board. This move is designed to leverage Dr. Ophir's scientific leadership for pipeline advancement while utilizing Dr. Cohen-Dayag's extensive experience to focus on long-term corporate strategy and key partnerships.